Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence

Detalles Bibliográficos
Autores principales: Frey, Nicolas, Bordogna, Walter, Balas, Bogdana, Ruf, Thorsten, Archer, Venice, Guerini, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291499/
https://www.ncbi.nlm.nih.gov/pubmed/34365647
http://dx.doi.org/10.1002/cpt.2373
_version_ 1784749149142384640
author Frey, Nicolas
Bordogna, Walter
Balas, Bogdana
Ruf, Thorsten
Archer, Venice
Guerini, Elena
author_facet Frey, Nicolas
Bordogna, Walter
Balas, Bogdana
Ruf, Thorsten
Archer, Venice
Guerini, Elena
author_sort Frey, Nicolas
collection PubMed
description
format Online
Article
Text
id pubmed-9291499
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92914992022-07-20 Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence Frey, Nicolas Bordogna, Walter Balas, Bogdana Ruf, Thorsten Archer, Venice Guerini, Elena Clin Pharmacol Ther Perspectives John Wiley and Sons Inc. 2021-08-08 2021-11 /pmc/articles/PMC9291499/ /pubmed/34365647 http://dx.doi.org/10.1002/cpt.2373 Text en © 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Perspectives
Frey, Nicolas
Bordogna, Walter
Balas, Bogdana
Ruf, Thorsten
Archer, Venice
Guerini, Elena
Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence
title Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence
title_full Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence
title_fullStr Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence
title_full_unstemmed Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence
title_short Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence
title_sort optimized alectinib dose regimen for treatment of patients with alk‐positive non‐small cell lung cancer based on robust pharmacometric analyses and clinical evidence
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291499/
https://www.ncbi.nlm.nih.gov/pubmed/34365647
http://dx.doi.org/10.1002/cpt.2373
work_keys_str_mv AT freynicolas optimizedalectinibdoseregimenfortreatmentofpatientswithalkpositivenonsmallcelllungcancerbasedonrobustpharmacometricanalysesandclinicalevidence
AT bordognawalter optimizedalectinibdoseregimenfortreatmentofpatientswithalkpositivenonsmallcelllungcancerbasedonrobustpharmacometricanalysesandclinicalevidence
AT balasbogdana optimizedalectinibdoseregimenfortreatmentofpatientswithalkpositivenonsmallcelllungcancerbasedonrobustpharmacometricanalysesandclinicalevidence
AT rufthorsten optimizedalectinibdoseregimenfortreatmentofpatientswithalkpositivenonsmallcelllungcancerbasedonrobustpharmacometricanalysesandclinicalevidence
AT archervenice optimizedalectinibdoseregimenfortreatmentofpatientswithalkpositivenonsmallcelllungcancerbasedonrobustpharmacometricanalysesandclinicalevidence
AT guerinielena optimizedalectinibdoseregimenfortreatmentofpatientswithalkpositivenonsmallcelllungcancerbasedonrobustpharmacometricanalysesandclinicalevidence

Ejemplares similares